NASDAQ:IMDX Oncocyte Q3 2025 Earnings Results & Report $1.77 -0.09 (-4.84%) As of 03:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Oncocyte reported Q3 2025 earnings on November 10, 2025. The company reported EPS of -$0.34, while revenue was $260 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeAfter Market Closes Oncocyte EPS ResultsActual EPS-$0.34Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncocyte Revenue ResultsActual Revenue$260 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Oncocyte Q3 2025 Earnings FAQ Did Oncocyte beat earnings estimates for Q3 2025? Oncocyte (NASDAQ:IMDX) reported earnings of -$0.34 per share for Q3 2025. The report was announced on Monday, November 10, 2025. What was Oncocyte's revenue for Q3 2025? Oncocyte reported revenue of $260 thousand for Q3 2025. Oncocyte Earnings HeadlinesInsight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call TranscriptNovember 17 at 5:00 AM | seekingalpha.comIMDx Reports Third Quarter 2026 Results and Provides Corporate UpdateNovember 16 at 4:56 PM | globenewswire.comEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score. Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score. Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed.November 17 at 1:00 AM | Pennie Financial (Ad)Insight Molecular Diagnostics Announces Proposed Public OfferingNovember 16 at 4:10 PM | globenewswire.comiMDx to Release Third Quarter Results on November 16, 2026November 5, 2026 | globenewswire.comOncocyte Corporation Registered ShsOctober 21, 2026 | markets.businessinsider.comSee More Oncocyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email. Email Address About OncocyteOncocyte (NASDAQ:IMDX)oration, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care. The company’s business has evolved from Oncocyte’s earlier focus on oncology diagnostics, including tests designed to help guide lung cancer treatment. Its current focus is transplant diagnostics, with services primarily directed to the U.S. healthcare market.View Oncocyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.